<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Pediatr</journal-id><journal-id journal-id-type="publisher-id">IJPD</journal-id><journal-title-group><journal-title>Iranian Journal of Pediatrics</journal-title></journal-title-group><issn pub-type="ppub">2008-2142</issn><issn pub-type="epub">2008-2150</issn><publisher><publisher-name>Tehran University of Medical Sciences</publisher-name><publisher-loc>Tehran, Iran</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25793067</article-id><article-id pub-id-type="pmc">4359413</article-id><article-id pub-id-type="publisher-id">IJPD-24-593</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Safety and Efficacy of Phenylephrine Nasal Drops in Bronchiolitis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Soleimani</surname><given-names>Gholamreza</given-names></name><degrees>MD</degrees><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Akbarpour</surname><given-names>Marzieh</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Mohammadi</surname><given-names>Mehdi</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Research Center for Children and Adolescents</aff><aff id="aff2"><label>2</label>Department of Pediatrics</aff><aff id="aff3"><label>3</label>Department of Epidemiology and Biostatistics, Zahedan University of Medical Sciences , Zahedan , Iran </aff><author-notes><corresp id="cor1"><label>*</label>Corresponding Author: Address: Research Center for Children and Adolescents Health, Zahedan University of Medical Sciences Ali- Ebne Abitaleb Hospital, Zahedan , Iran<email>soleimanimd@yahoo.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2014</year></pub-date><pub-date pub-type="epub"><day>5</day><month>10</month><year>2014</year></pub-date><volume>24</volume><issue>5</issue><fpage>593</fpage><lpage>597</lpage><history><date date-type="received"><day>14</day><month>11</month><year>2013</year></date><date date-type="accepted"><day>25</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 by Pediatrics Center of Excellence, Children&#x02019;s Medical Center, Tehran University of Medical Sciences, All rights reserved</copyright-statement><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<bold><italic>Objective:</italic></bold> Bronchiolitis is a common lower respiratory tract infection in the first year of life. In this disease upper respiratory tract infection is associated with nasal congestion, respiratory distress and hypoxia. We studied the effect of phenylephrine drops as a decongestant in treatment of light and moderately severe cases of acute bronchiolitis.</p><p>
<bold><italic>Methods:</italic></bold> This is a double blind randomized trial involving 100 children aged 4 weeks to 12 months. The patients were divided into two groups, the first group received 0.1 ml phenylephrine 0.5% and the second group 0.1 ml sodium chloride (NaCl) 0.9% as placebo in both nostrils. Respiratory rate, heart rate, O2 saturation, dyspnea, retractions and wheezing were assessed before and 30 minutes after medication.</p><p>
<bold><italic>Findings:</italic></bold> After medication, O2 saturation and respiratory muscles retractions in the phenylephrine group were significantly better than those of the placebo group (<italic>P</italic>=0.004 and <italic>P</italic>=0.002, respectively). In the phenylephrine group, O2 saturation, retractions and wheezing were also significantly better before than those after medication (<italic>P</italic>=0.003 and <italic>P</italic>&#x0003c;0.0001 respectively). In the placebo group no significant difference before and after intervention was observed.</p><p>
<bold><italic>Conclusion:</italic></bold> Phenylephrine as a topical decongestant is an inexpensive, easily available and suitable means in the treatment of mild to moderately severe bronchiolitis.</p></abstract><kwd-group><title>Key Words</title><kwd>Respiratory Tract</kwd><kwd>Bronchiolitis</kwd><kwd>Alpha Agonist</kwd><kwd>Phenylephrine</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Acute bronchiolitis is the most common lower respiratory tract infection in the first year of life and also the most common reason for the infants&#x02019; hospitalization during winter season<sup>[</sup><sup><xref rid="B1" ref-type="bibr">1</xref></sup><sup>,</sup><sup><xref rid="B2" ref-type="bibr">2</xref></sup><sup>]</sup>, respiratory syncytial virus being the most common cause. Unfortunately no remarkable progress in its treatment is achieved in recent years<sup>[</sup><sup><xref rid="B3" ref-type="bibr">3</xref></sup><sup>]</sup>.</p><p> Involvement of upper airways in bronchiolitis leads to nasal congestion, inadequate oral intake, dehydration, respiratory distress and hypoxemia <sup>[</sup><sup><xref rid="B2" ref-type="bibr">2</xref></sup><sup>]</sup>. Therefore, nasal decongestants may relieve the signs and symptoms related to upper airway obstruction. Phenylephrine as an alpha-agonist is supposed to reduce nasal edema<sup>[</sup><sup><xref rid="B4" ref-type="bibr">4</xref></sup><sup>]</sup>.</p><p> The effect of epinephrine<sup>[</sup><sup><xref rid="B5" ref-type="bibr">5</xref></sup><sup>-</sup><sup><xref rid="B7" ref-type="bibr">7</xref></sup><sup>]</sup>, inhaled furosemide<sup>[</sup><sup><xref rid="B1" ref-type="bibr">1</xref></sup><sup>]</sup>, inhaled hypertonic saline<sup>[</sup><sup><xref rid="B8" ref-type="bibr">8</xref></sup><sup>-</sup><sup><xref rid="B10" ref-type="bibr">10</xref></sup><sup>]</sup>, xylomethazoline<sup>[</sup><sup><xref rid="B2" ref-type="bibr">2</xref></sup><sup>]</sup>, phenylephrine<sup>[</sup><sup><xref rid="B4" ref-type="bibr">4</xref></sup><sup>]</sup>, dexamethasone <sup>[</sup><sup><xref rid="B11" ref-type="bibr">11</xref></sup><sup>]</sup> and zinc sulfate<sup>[</sup><sup><xref rid="B12" ref-type="bibr">12</xref></sup><sup>]</sup> has been investigated in treatment of bronchiolitis. Nevertheless, the only non-controversial treatment remains supportive therapy<sup>[</sup><sup><xref rid="B3" ref-type="bibr">3</xref></sup><sup>]</sup>.</p><p> The results of studies on the effect of &#x003b1;-blockers as decongestant are controversial. Therefore, we tried to compare the effect of intranasal phenylephrine (as a decongestant) with sodium chloride (NaCl) 0.9% (as placebo).</p></sec><sec sec-type="methods"><title>Subjects and Methods</title><p>This double blind randomized clinical study was conducted in <italic>Ali</italic><italic>-</italic>Ebne<italic>-</italic><italic>Abitaleb</italic> hospital, Zahedan, Southeast Iran. All patients aged 4 weeks to 12 months with clinical diagnosis of viral bronchiolitis were eligible for the study. Clinical diagnosis of viral bronchiolitis was based on the first episodes of wheezing in infants with a viral upper respiratory tract infection<sup>[</sup><sup><xref rid="B13" ref-type="bibr">13</xref></sup><sup>]</sup>. Wheezing was evaluated with a stethoscope and defined as end-expiratory or expiratory according to the physician&#x02019;s hearing. Oxygen therapy was defined as oxygen supply via head box to increase blood O<sub>2</sub> saturation to more than 90 percent.</p><p> Patients with following criteria were excluded: gestational age less than 34 weeks; heart rate more than 200 beats/min; respiratory rate &#x0003e;70 breaths/min; use of &#x003b1;- or &#x003b2;-agonists during 24 hours before admission; hypotension; chronic disease, history of atopia in first degree relatives, known cases of cystic fibrosis and any signs and symptoms of severe bronchiolitis.</p><p> The medical staff involved in the study was blinded. Both drops were smell- and colorless and just labeled A and B. Based on permuted-block randomization, patients were allocated to receive phenylephrine 0.5% drop (A) or NaCl 0.9% drop (B) in both nostrils while in supine position and remained in this position for one minute.</p><p> Case and control group both received routine treatment for bronchiolitis (O<sub>2</sub> therapy, salbutamol spray, nasal suction and neubulizer). Case group received in addition phenylephrine 0.5%, one drop in each nostril, which was replaced by NaCl 0.9% in the control group.</p><p> O<sub>2</sub> saturation, respiratory rate, heart rate, retractions, dyspenea and wheezing were evaluated by the same investigator thirty minutes after administration of the drug and placebo.</p><p> Dyspenea was defined as one or more of the following items: difficulty in feeding; decreased vocalization, and/or agitation. Retractions were noted as no retractions, intercostal retractions or </p><p>subcostal+inter-costal retractions.</p><p> To determine the sample size, mean respiratory rate was taken to be 43 in treatment and 42 in control group with 1.6 as standard deviation<sup>[</sup><sup><xref rid="B4" ref-type="bibr">4</xref></sup><sup>]</sup>, 5% and 20% type I and II error respectively. Therefore sample size was calculated to be 50 patients in each group.</p><p> Analyses of data were done by the SPSS (version 16) using chi-square, Wilcoxon, Kruskal-Wallis and independent sample t-test. The level of significance was considered according to 95% confidence interval. </p></sec><sec><title>Findings</title><p>One hundred and seven patients (38% boys) between 4 weeks and 1 year old (mean age 6.02&#x000b1;3.2 months) were eligible to participate in the study. Seven patients were excluded because of prematurity (2 cases), unstable vital signs (2 cases), severe bronchiolitis (2 cases), or congenital heart disease (1 case). </p><p> In the initial examination there was no significant difference between the two groups in demographic data including heart rate, respiratory rate, O<sub>2</sub> saturation, retrac-tions, wheezing, and dyspnea (<xref ref-type="table" rid="T1">Table 1</xref>).</p><p> Thirty minutes after administration of phenylephrine drops, O<sub>2</sub> saturation significantly increased in group A (<italic>P</italic>=0.004) whereas the severity of retractions significantly decreased (<xref ref-type="table" rid="T2">Table 2</xref>).</p><p> Comparison of data showed that O<sub>2</sub> saturation significantly increased in the case group after phenylephrine drops (<italic>P</italic>=0.003) and the severity of retractions and wheezing significantly decreased (<italic>P</italic>&#x0003c;0.0001 and <italic>P</italic>=0.006 respectively) (<xref ref-type="table" rid="T3">Table 3</xref>).</p><p> There were no statistical differences in any of the outcome measures in group B before and after medication (<xref ref-type="table" rid="T4">Table 4</xref>). No adverse effect was seen after application of the decongestant.</p></sec><sec sec-type="discussion"><title>Discussion</title><p>This study demonstrated that phenylephrine (as a nasal decongestant) is more effective than normal saline solution (as a placebo) to treat acute bronchiolitis and reduce clinical severity of the symptoms.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Demographic characteristics and pre-treatment data</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#000080; color:#FFFFFF;" align="justify" valign="middle" colspan="2" rowspan="1">
<bold>Parameter</bold>
</th><th style="background-color:#000080; color:#FFFFFF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Phenylephrine (n=50)</bold>
</th><th style="background-color:#000080; color:#FFFFFF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>NaCl (n=50)</bold>
</th><th style="background-color:#000080; color:#FFFFFF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold><italic>P</italic></bold>
<bold>. value</bold>
</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">
<bold>Age </bold>
</td><td align="justify" rowspan="1" colspan="1"/><td align="center" valign="middle" rowspan="1" colspan="1">6.6 (3.4)<xref ref-type="table-fn" rid="TFN1">&#x003b1;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">5.4 (3.04)<xref ref-type="table-fn" rid="TFN1">&#x003b1;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">0.08</td></tr><tr><td style="background-color:#F0F0FF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Sex</bold>
</td><td style="background-color:#F0F0FF;" align="right" rowspan="1" colspan="1">Male<break/>Female</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">21 (42%)<break/>29 (58%)</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">17 (34%)<break/>33 (66%)</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Retraction</bold>
</td><td align="right" rowspan="1" colspan="1">No retractions<break/>Intercostal<break/>Subcostal + intercostal</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (10%)<break/>19 (38%)<break/>26 (52%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2%)<break/>23 (46%)<break/>26 (52%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7</td></tr><tr><td style="background-color:#F0F0FF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Dyspnea</bold>
</td><td style="background-color:#F0F0FF;" align="right" rowspan="1" colspan="1">NL feeding, vocalization and activity <break/>One of the following: difficulty in feeding; decreased vocalization; or agitation <break/>Two of the following: difficulty in feeding, decreased vocalization, and/or agitation </td><td style="background-color:#F0F0FF;" align="center" rowspan="1" colspan="1">5 (10%)<break/>25 (50%)<break/>20 (40%)</td><td style="background-color:#F0F0FF;" align="center" rowspan="1" colspan="1">7 (14%)<break/>14 (28%)<break/>29 (58%)</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Wheeze</bold>
</td><td align="right" rowspan="1" colspan="1">End-expiratory<break/>Expiratory</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (28%)<break/>36 (72%)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (34%)<break/>33 (66%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td></tr><tr><td style="background-color:#F0F0FF;" align="left" colspan="2" rowspan="1">
<bold>O</bold>
<sub>2</sub>
<bold> saturation</bold>
</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">93.1 (4.2)<xref ref-type="table-fn" rid="TFN1">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">92.1 (4.03)<xref ref-type="table-fn" rid="TFN1">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.2</td></tr><tr><td align="justify" colspan="2" rowspan="1">
<bold>Respiratory rate</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">44.7 (9.3)<xref ref-type="table-fn" rid="TFN1">&#x003b1;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">47.5 (9.5)<xref ref-type="table-fn" rid="TFN1">&#x003b1;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td></tr><tr><td style="background-color:#F0F0FF;" align="justify" colspan="2" rowspan="1">
<bold>Heart rate</bold>
</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">115.3 (9.9)<xref ref-type="table-fn" rid="TFN1">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">118.2 (8.7)<xref ref-type="table-fn" rid="TFN1">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.1</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>&#x003b1;</label><p> : Mean (Standard Deviation); NaCl: Sodium Chloride</p></fn></table-wrap-foot></table-wrap><p>Alpha-adrenergics produce vasoconstriction and decrease blood flow through microvesseles, leading to decreased resistance to airflow by reducing hyperemia, mucosa swelling, plasma exudation and nasal secretions<sup>[</sup><sup><xref rid="B13" ref-type="bibr">13</xref></sup><sup>]</sup>. In allergic rhinitis, oral and topical decongestants cause vasoconstriction and oppose vasodilation in the nasal mucosa, thus decreasing inflammation and reducing nasal airway resistance so that the nasal congestion is diminished and nose breathing faci-litated<sup>[</sup><sup><xref rid="B14" ref-type="bibr">14</xref></sup><sup>,</sup><sup><xref rid="B15" ref-type="bibr">15</xref></sup><sup>]</sup>.</p><p> There is a wide-range of practice in the management of bronchiolitis<sup>[</sup><sup><xref rid="B16" ref-type="bibr">16</xref></sup><sup>]</sup> but there are limited studies available on the effect of nasal decongestants in the treatment of pediatric bronchiolitis<sup>[</sup><sup><xref rid="B2" ref-type="bibr">2</xref></sup><sup>,</sup><sup><xref rid="B4" ref-type="bibr">4</xref></sup><sup>]</sup>. According to American Academy of Pediatrics a consistent benefit from &#x003b1;-adrenergic or &#x003b2;-adrenergic agents for bronchiolitis treatment is controversial. So, &#x003b1;-adrenergic or &#x003b2;-adrenergic medication is an option to be more investigated<sup>[</sup><sup><xref rid="B17" ref-type="bibr">17</xref></sup><sup>]</sup>. In a study, nasal decongestant (xylometazoline) was as effective as epinephrine in the treatment of acute bronchiolitis, so it was concluded that upper respiratory tract diseases have an important effect on clinical presentation and pathogenesis of bronchiolitis<sup>[</sup><sup><xref rid="B2" ref-type="bibr">2</xref></sup><sup>]</sup>. Another study assessed the effect of nasal phenyephrine in infants hospitalized for bronchiolitis and concluded that respiratory status does not change after short term use of topical nasal phenylephrine.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Comparison of data between phenylephrine and placebo 30 minutes after application</p></caption><table frame="hsides" rules="groups"><tbody><tr><td style="background-color:#000080; color:#FFFFFF;" align="justify" colspan="2" rowspan="1">
<bold>Parameter</bold>
</td><td style="background-color:#000080; color:#FFFFFF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Phenylephrine (n=16)</bold>
</td><td style="background-color:#000080; color:#FFFFFF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>NaCl (n=16)</bold>
</td><td style="background-color:#000080; color:#FFFFFF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold><italic>P. </italic></bold>
<bold>value</bold>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Retraction</bold>
</td><td align="right" rowspan="1" colspan="1">No retractions<break/>Intercostal<break/>Subcostal + intercostal</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (16%)<break/>29 (58%)<break/>13 (26%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0%)<break/>25 (50%)<break/>25 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002</td></tr><tr><td style="background-color:#F0F0FF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Dyspnea</bold>
</td><td style="background-color:#F0F0FF;" align="right" rowspan="1" colspan="1">NL feeding, vocalization and activity<break/>One of the following: difficulty in feeding; decreased vocalization; or agitation <break/>Two of the following; difficulty in feeding; decreased vocalization; and/or agitation </td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">4 (8%)<break/>30 (60%)<break/>16 (32%)</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">8 (16%)<break/>13 (26%)<break/>29 (58%)</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Wheeze</bold>
</td><td align="right" rowspan="1" colspan="1">No wheeze<break/>End-expiratory<break/>Expiratory</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (6%)<break/>18 (36%)<break/>29 (58%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0%)<break/>19 (38%)<break/>31 (62%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td></tr><tr><td style="background-color:#F0F0FF;" align="left" colspan="2" rowspan="1">
<bold>O</bold>
<sub>2</sub>
<bold> saturation</bold>
</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">94.1 (3.7)<xref ref-type="table-fn" rid="TFN2">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">91.9 (3.5)<xref ref-type="table-fn" rid="TFN2">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>Respiratory rate</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">43.9 (9.1)<xref ref-type="table-fn" rid="TFN2">&#x003b1;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">47.2 (9.5)<xref ref-type="table-fn" rid="TFN2">&#x003b1;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td></tr><tr><td style="background-color:#F0F0FF;" align="left" colspan="2" rowspan="1">
<bold>Heart rate</bold>
</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">114.3 (9.7)<xref ref-type="table-fn" rid="TFN2">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">118.1 (10.7)<xref ref-type="table-fn" rid="TFN2">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.06</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><label>&#x003b1;</label><p>: Mean (Standard Deviation); NaCl: Sodium Chloride</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Comparison of data before and 30 minutes after phenylephrine application</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#000080; color:#FFFFFF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Parameter</bold>
</th><th style="background-color:#000080; color:#FFFFFF;" align="justify" colspan="2" rowspan="1"/><th style="background-color:#000080; color:#FFFFFF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Before (n=50)</bold>
</th><th style="background-color:#000080; color:#FFFFFF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>After (n=50)</bold>
</th><th style="background-color:#000080; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold><italic>P. </italic></bold>
<bold>value</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Retraction</bold>
</td><td align="right" rowspan="1" colspan="1">No retraction<break/>Intercostal<break/>Subcostal+intercostal</td><td align="center" valign="middle" colspan="2" rowspan="1">5 (10%)<break/>19 (83%)<break/>26 (52%)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (16%)<break/>29 (58%)<break/>13 (26%)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td style="background-color:#F0F0FF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Dyspnea</bold>
</td><td style="background-color:#F0F0FF;" align="right" rowspan="1" colspan="1">NL feeding, vocalization and activity <break/>One of the following: difficulty in feeding; decreased vocalization; or agitation<break/>Two of the following: difficulty in feeding; decreased vocalization; and/or agitation </td><td style="background-color:#F0F0FF;" align="center" colspan="2" rowspan="1">5 (10%)<break/>25 (50%)<break/>20 (40%)</td><td style="background-color:#F0F0FF;" align="center" rowspan="1" colspan="1">4 (8%)<break/>30 (60%)<break/>16 (32%)</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Wheeze</bold>
</td><td align="right" rowspan="1" colspan="1">No wheeze<break/>End-expiratory<break/>Expiratory</td><td align="center" valign="middle" colspan="2" rowspan="1">0 (0%)<break/>4 (28%)<break/>36 (72%)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (6%)<break/>18 (36%)<break/>29 (58%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006</td></tr><tr><td style="background-color:#F0F0FF;" align="left" colspan="2" rowspan="1">
<bold>O</bold>
<sub>2</sub>
<bold> saturation</bold>
</td><td style="background-color:#F0F0FF;" align="center" valign="middle" colspan="2" rowspan="1">93.1 (4.2)<xref ref-type="table-fn" rid="TFN3">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">94.1 (3.7)<xref ref-type="table-fn" rid="TFN3">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" colspan="2" rowspan="1">
<bold>Respiratory rate</bold>
</td><td align="center" valign="middle" colspan="2" rowspan="1">44.7 (9.3)<xref ref-type="table-fn" rid="TFN3">&#x003b1;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">43.9 (9.09)<xref ref-type="table-fn" rid="TFN3">&#x003b1;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">0.07</td></tr><tr><td style="background-color:#F0F0FF;" align="left" colspan="2" rowspan="1">
<bold>Heart rate</bold>
</td><td style="background-color:#F0F0FF;" align="center" valign="middle" colspan="2" rowspan="1">115.3 (9.9)<xref ref-type="table-fn" rid="TFN3">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">114.3 (9.7)<xref ref-type="table-fn" rid="TFN3">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.2</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><label>&#x003b1;</label><p> : Mean (Standard Deviation); NaCl: Sodium Chloride</p></fn></table-wrap-foot></table-wrap><p>This seemed to be attributed to strict inclusion and exclusion criteria, parental refusal and lack of study personnel on weekends and nights<sup>[</sup><sup><xref rid="B4" ref-type="bibr">4</xref></sup><sup>]</sup>. Diagnostic tests such as radiography and viral antigen test can be applied to confirm diagnosis, although clinical diagnosis is decisive<sup>[</sup><sup><xref rid="B18" ref-type="bibr">18</xref></sup><sup>,</sup><sup><xref rid="B19" ref-type="bibr">19</xref></sup><sup>]</sup>. Therefore our patients were diagnosed clinically. In accordance with previous studies<sup>[</sup><sup><xref rid="B2" ref-type="bibr">2</xref></sup><sup>,</sup><sup><xref rid="B4" ref-type="bibr">4</xref></sup><sup>]</sup>, we observed no adverse effects of phenylephrine as a topical nasal decongestant and found it safe in short course usage. Rebound nasal congestion does not appear after a single dose but it might be seen after recurrent doses<sup>[</sup><sup><xref rid="B4" ref-type="bibr">4</xref></sup><sup>]</sup>.</p><p> Short time assessment of decongestant effect can be seen as a limitation of our study. More studies with frequent usage of the decongestant are needed to determine suitable dosage, duration of therapy, and long term follow up to validate systemic and topical effect and eventual side effects (such as rebound) of the lhenylephrine nasal drops more exactly.</p><table-wrap id="T4" position="float"><label>Table 4</label><caption><p>Comparison of data before and 30 minutes after normal NaCl application</p></caption><table frame="hsides" rules="groups"><thead><tr><th style="background-color:#000080; color:#FFFFFF;" align="justify" rowspan="1" colspan="1">
<bold>Parameter</bold>
</th><th style="background-color:#000080; color:#FFFFFF;" align="justify" rowspan="1" colspan="1"/><th style="background-color:#000080; color:#FFFFFF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>Before (n=50)</bold>
</th><th style="background-color:#000080; color:#FFFFFF;" align="center" valign="middle" rowspan="1" colspan="1">
<bold>After (n=50)</bold>
</th><th style="background-color:#000080; color:#FFFFFF;" align="center" rowspan="1" colspan="1">
<bold><italic>P</italic></bold>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Retraction</bold>
</td><td align="right" rowspan="1" colspan="1">No retractions<break/>Intercostal<break/>Subcostal &#x00026; intercostal</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (2%)<break/>23 (46%)<break/>26 (52%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0%)<break/>25 (50%)<break/>25 (50%)</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td style="background-color:#F0F0FF;" align="left" valign="middle" rowspan="1" colspan="1">
<bold>Dyspnea</bold>
</td><td style="background-color:#F0F0FF;" align="right" rowspan="1" colspan="1">NL feeding, vocalization and activity <break/>One of the following: difficulty in feeding; decreased vocalization, or agitation <break/>Two of the following: difficulty in feeding, decreased vocalization, and/or agitation </td><td style="background-color:#F0F0FF;" align="center" rowspan="1" colspan="1">7 (14%)<break/>14 (28%)<break/>29 (58%)</td><td style="background-color:#F0F0FF;" align="center" rowspan="1" colspan="1">8 (16%)<break/>13 (26%)<break/>29 (58%)</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0. 65</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<bold>Wheeze</bold>
</td><td align="right" rowspan="1" colspan="1">No wheeze<break/>End-expiratory<break/>Expiratory</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0%)<break/>17 (34%)<break/>33 (66%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0%)<break/>19 (38%)<break/>31 (62%)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.15</td></tr><tr><td style="background-color:#F0F0FF;" align="justify" colspan="2" rowspan="1">
<bold>O</bold>
<sub>2</sub>
<bold> saturation</bold>
</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">92.1 (4.03)<xref ref-type="table-fn" rid="TFN4">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">91.9 (3.5)<xref ref-type="table-fn" rid="TFN4">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.57</td></tr><tr><td align="justify" colspan="2" rowspan="1">
<bold>Respiratory rate</bold>
</td><td align="center" valign="middle" rowspan="1" colspan="1">47.5 (9.5)<xref ref-type="table-fn" rid="TFN4">&#x003b1;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">47.2 (9.5)<xref ref-type="table-fn" rid="TFN4">&#x003b1;</xref></td><td align="center" valign="middle" rowspan="1" colspan="1">0.17</td></tr><tr><td style="background-color:#F0F0FF;" align="justify" colspan="2" rowspan="1">
<bold>Heart rate</bold>
</td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">118.2 (8.7)<xref ref-type="table-fn" rid="TFN4">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">118.1 (10.7)<xref ref-type="table-fn" rid="TFN4">&#x003b1;</xref></td><td style="background-color:#F0F0FF;" align="center" valign="middle" rowspan="1" colspan="1">0.95</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><label>&#x003b1;</label><p>
<sup>: Mean (Standard Deviation); NaCl: Sodium Chloride</sup></p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Intranasal phenylephrine as an alpha-adrenergic decongestant, in combi-nation with supportive therapy in bronchiolitis, is a safe, not expensive and effective treatment for mild to moderate viral bronchiolitis for both inpatient and outpatient treatment. Further studies are needed to determine the optimal dosing and time interval to identify the maximum effect.</p></sec></body><back><ack><title>Acknowledgment</title><p>This study was approved by the Ethics Committee of Zahedan University of Medical Sciences (Registry code: 89-2564).</p></ack><sec><title/><p>
<bold><italic>Conflict of Interest: </italic></bold>None</p></sec><sec><title>Authors&#x02019; Contribution</title><p>G. Soleimani: Concept and Design, Critical Revision of the Manuscript </p><p>M. Akbarpour: Acquisition of Data, Manuscript Preparation</p><p>M. Mohammadi: Data Analysis and Interpretation, </p><p>All authors Approved final version of the paper.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bar</surname><given-names>A</given-names></name><name><surname>Srugo</surname><given-names>I</given-names></name><name><surname>Amirav</surname><given-names>I</given-names></name><etal/></person-group><article-title>Inhaled furosemide in hospitalized infants with viral bronchiolitis: a randomized, double-blind placebo-controlled pilot study</article-title><source> Pediatr Pulmonol</source><year>2008</year><volume>43</volume><issue>3</issue><fpage>261</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">18214942</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Livni</surname><given-names>G</given-names></name><name><surname>Rachmel</surname><given-names>A</given-names></name><name><surname>Marom</surname><given-names>D</given-names></name><etal/></person-group><article-title>A randomized, double-blind study examining the comparative efficacies and safety of inhaled epinephrine and nasal decongestant in hospitalized infants with acute bronchiolitis</article-title><source> Pediatr Infect Dis J</source><year>2010</year><volume>29</volume><issue>1</issue><fpage>71</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">19907355</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sethi</surname><given-names>GR</given-names></name><name><surname>Nagar</surname><given-names>G</given-names></name></person-group><article-title>Evidence based treatment of bronchiolitis</article-title><source> Indian J Pediatr</source><year>2004</year><volume>71</volume><issue>8</issue><fpage>733</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15345876</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ralston</surname><given-names>Sh</given-names></name><name><surname>Roohi</surname><given-names>M</given-names></name></person-group><article-title>A randomized, controlled trial of nasal phenylephrine in infants hospitalized for bronchiolitis</article-title><source> J Pediatr</source><year>2008</year><volume>153</volume><issue>6</issue><fpage>795</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18657831</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wainwright</surname><given-names>C</given-names></name><name><surname>Altamirano</surname><given-names>L</given-names></name><name><surname>Cirujuno</surname><given-names>M</given-names></name></person-group><article-title>A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infant with acute bronchiolitis</article-title><source> N Engl J Med</source><year>2003</year><volume>349</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">12840089</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Numa</surname><given-names>HA</given-names></name><name><surname>Williams</surname><given-names>GD</given-names></name><name><surname>Dakin</surname><given-names>CJ</given-names></name></person-group><article-title>The effect of nebulized epinephrine on respiratory mechanics and gas exchange in bronchiolitis</article-title><source> Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><issue>1</issue><fpage>86</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">11435244</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modaressi</surname><given-names>M</given-names></name><name><surname>Asadian</surname><given-names>A</given-names></name><name><surname>Faghihinia</surname><given-names>J</given-names></name></person-group><article-title>Comparison of epinephrine to salbutamol in acute bronchiolitis</article-title><source> Iran J Pediatr</source><year>2012</year><volume>22</volume><issue>2</issue><fpage>241</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">23056893</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhry</surname><given-names>K</given-names></name><name><surname>Sinert</surname><given-names>R</given-names></name></person-group><article-title>Is nebulized hypertonic saline solution an effective treatment for bronchiolitis in infants?</article-title><source>Ann Emerg Med </source><year>2010</year><volume>55</volume><issue>1</issue><fpage>120</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">19464073</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuzik</surname><given-names>BA</given-names></name><name><surname>Al</surname><given-names>Qadhi SA</given-names></name><name><surname>Kent</surname><given-names>S</given-names></name><etal/></person-group><article-title>Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants</article-title><source> J Pediatr</source><year>2007</year><volume>151</volume><issue>3</issue><fpage>266</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">17719935</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuzik</surname><given-names>BA</given-names></name><name><surname>Flavin</surname><given-names>MP</given-names></name><name><surname>Kent</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of inhaled hypertonic saline on hospital admission rate in children with viral bronchiolitis: a randomized trial</article-title><source> CJEM</source><year>2010</year><volume>12</volume><issue>6</issue><fpage>477</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">21073773</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corneli</surname><given-names>HM</given-names></name><name><surname>Zorc</surname><given-names>JJ</given-names></name><name><surname>Mahajan</surname><given-names>P</given-names></name><etal/></person-group><article-title>A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis</article-title><source> N Engl J Med</source><year>2007</year><volume>357</volume><issue>26</issue><fpage>331</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17652648</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heydarian</surname><given-names>F</given-names></name><name><surname>Behmanesh</surname><given-names>F</given-names></name><name><surname>Daluee</surname><given-names>M</given-names></name><etal/></person-group><article-title>The role of zinc sulfate in acute bronchiolitis in patients aged 2 to 23 months</article-title><source> Iran J Pediatr</source><year>2012</year><volume>22</volume><issue>1</issue><fpage>231</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">23056891</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>JL</given-names></name></person-group><article-title>What works in bronchiolitis? </article-title><source>Indian Pediatrics</source><year> 2009</year><volume>46</volume><issue>2</issue><fpage>154</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">19242034</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corboz</surname><given-names>MR</given-names></name><name><surname>Rivelli</surname><given-names>MA</given-names></name><name><surname>Mingo</surname><given-names>GG</given-names></name><etal/></person-group><article-title>Mechanism of decongestant activity of alpha2-adrenoceptor agonists</article-title><source> Pulm Pharmacol Therap</source><year>2008</year><volume>21</volume><issue>3</issue><fpage>449</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">17869148</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sur</surname><given-names>DK</given-names></name><name><surname>Scandale</surname><given-names>S</given-names></name></person-group><article-title>Treatment of allergic rhinitis</article-title><source> SA Fam Pract</source><year>2010</year><volume>52</volume><issue>5</issue><fpage>398</fpage><lpage>403</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clover</surname><given-names>RD</given-names></name></person-group><article-title>Clinical Practice Guideline for Bronchiolitis: Key Recommendations</article-title><source> Am Fam Physician</source><year>2007</year><volume>75</volume><issue>2</issue><fpage>171</fpage><pub-id pub-id-type="pmid">17263213</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><article-title>American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis: Diagnosis and management of bronchiolitis</article-title><source>Pediatrics</source><year> 2006</year><volume>118</volume><issue>4</issue><fpage>1774</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">17015575</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorc</surname><given-names>JJ</given-names></name><name><surname>Hall</surname><given-names>CB</given-names></name></person-group><article-title>Bronchiolitis: recent evidence on diagnosis and management</article-title><source> Pediatrics</source><year>2010</year><volume>125</volume><issue>2</issue><fpage>342</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">20100768</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>T</given-names></name></person-group><article-title>Bronchiolitis</article-title><source> Innov Ai T</source><year>2011</year><volume>4</volume><issue>7</issue><fpage>379</fpage><lpage>84</lpage></element-citation></ref></ref-list></back></article>